Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Inclusion Criteria: Histologically confirmed intracranial glioblastoma multiforme (GBM) Original diagnosis of low-grade glioma with subsequent histological confirmation of GBM allowed Recurrent disease Failed prior radiotherapy Must require a surgical procedure (gross total or near gross total resection) for tumor removal Performance status - Karnofsky 60-100% White Blood Count (WBC) ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL (transfusion allowed) Serum glutamic oxaloacetic transaminase (SGOT) < 2 times upper limit of normal (ULN) Bilirubin < 2 times ULN Creatinine < 1.5 mg/dL Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception during and for ≥ 2 weeks after study participation (for female patients) or for 3 months after study participation (for male patients) No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix No active infection No other significant uncontrolled medical illness that would preclude study participation At least 3 weeks since prior interferon No prior cilengitide No other prior targeted antiangiogenic treatment (e.g., vatalanib, SU5416, or thalidomide) No concurrent anticancer immunotherapy No concurrent routine prophylactic filgrastim (G-CSF) At least 2 weeks since prior vincristine At least 3 weeks since prior procarbazine At least 6 weeks since prior nitrosoureas No concurrent anticancer chemotherapy At least 3 weeks since prior tamoxifen No concurrent anticancer hormonal therapy See Disease Characteristics At least 4 weeks since prior radiotherapy No concurrent anticancer radiotherapy Recovered from all prior therapies No more than 3 prior treatments for GBM (1 initial treatment; and treatment for 2 relapses) For patients who received prior therapy for low-grade glioma, a subsequent surgical diagnosis of high-grade glioma is considered the first relapse At least 4 weeks since prior investigational agents At least 4 weeks since prior cytotoxic therapy At least 3 weeks since other prior non-cytotoxic therapy (e.g., isotretinoin), except radiosensitizers No other concurrent anticancer therapy No other concurrent investigational agents